| abstract |
The present invention provides an inhibitor of the complement pathway for the treatment of eye diseases. The present invention relates to age-related macular degeneration (AMD), diabetic retinopathy, ocular angiogenesis (such as ocular neovascularization affecting choroid, cornea, or retinal tissue), and complement activation. It is related with the complement inhibitor which treats the pathological condition or disease relevant to eyes, such as the other ocular pathological condition which concerns on a. Treatment of AMD includes both dry and wet types of AMD. The complement inhibitors of the present invention include second complement pathways such as factor D, properdin, factor B, factor Ba, and factor Bb, and C3a, C5, C5a, C5b, C6, C7, C8, C9, and Inhibitors that inhibit the classical complement pathway such as, but not limited to, C5b-9. [Selection figure] None |